Virtual Library
Start Your Search
Amanda Rosberg
Author of
-
+
EP1.04 - Immuno-oncology (ID 194)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.04-35 - Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Experiences from Clinical Practice – Sweden (Now Available) (ID 1002)
08:00 - 18:00 | Author(s): Amanda Rosberg
- Abstract
Background
Lung cancer is the leading cause of cancer-related mortality worldwide, with NSCLC accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients (pts) with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated durable responses and represent the opportunity of a new treatment approach for pts with NSCLC.
Method
A chart review was conducted of incident cases of all pts who had been treated with immune check point inhibitor during the last 3 years in 4 hospitals. Data was retrospectively collected: pts characteristics, tumour characteristics, treatment details, tumor stage, adverse events, survival.
Result
In total, 244 pts, 114 (46.8%) males were given immunotherapy. Mean and median age was 70.11, 72.3 yrs. 219 (89.6%) were smoker or former smoker. 168 (68.9%) with PS 0-1, 61 (24.9%) PS 2. Most of the pts had stage IVA 119(48.6%), IIIB 34 (13.9%), IIIA 31 (12.7%). Adenocarcinoma in 151 (61.6%) and squamous cell carcinoma in 70(29.6%) of the pts. PDL1 < 1% in 30(12.2%), 1-49% in 66(27.3%) and >50% in 92 (37.6%). Pembrolizumab was given either as 1st or 2nd line in 120 (49.0%) ,nivolumab as 2nd, 3rd or 4th line in 85 (34.7%) and atezolizumab 31 (12.7%) as 2nd or 3rd line. 76(31.1%) had partial response,3 (1.2%) complete response, 41 (16.8%) stable disease, 64 (26.2%) progressive disease. 60 (24.5%) still on treatment. Most adverse events (AE) was pneumonitis 13 (5.2%), colitis 10 (4.1%), Thyroiditis 8 (3.2%).
Conclusion
Pembrolizumab has been given mostly in first line treatment due to high PD-L1 but nivolumab or tecentriq most in 2nd or 3rd line. Overall responses was 49.1%. Very few AE mostly pneumonitis and colitis
More data will be presented during the conference